Published online Nov 27, 2026. doi: 10.4254/wjh.125240
Revised: September 1, 2026
Accepted: November 5, 2026
Published online: November 27, 2026
Processing time: 141 Days and 8.2 Hours
Chronic liver diseases are heterogeneous and include autoimmune, genetic, me
To map the extent, nature, and characteristics of N-of-1 trials in liver diseases and identify research gaps.
We followed the Joanna Briggs Institute methodology for scoping reviews and PRISMA extension for Scoping Reviews reporting standards, using the Popula
Of 76 records identified, 2 empirical N-of-1 studies met the eligibility criteria. One evaluated oral thiamine in 3 patients with chronic hepatitis B and reported reduced aminotransferase levels and improved virological markers using t-tests. However, the pooled analysis of data from only 3 patients was statistically problematic and should not be considered strong evidence. The second study evaluated ursodeoxycholic acid in a patient with hepatic sarcoidosis over four crossover cycles and demonstrated improvement in cholestasis using a Wilcoxon test for paired data. The optional narrative appraisal found that both studies lacked randomization and blinding and did not use pre-specified protocols, raising concerns about internal validity.
No identified study used aggregated N-of-1 analyses, Bayesian methods, or frameworks for integrating N-of-1 evidence into clinical decision-making. N-of-1 trials remain markedly underused in hepatology despite the pre
Core Tip: Many rare, chronic, and stable liver diseases are difficult to investigate using conventional randomized controlled trials. N-of-1 trials are randomized, multiple-crossover trials designed to evaluate treatment effects in an individual patient. In this scoping review, we identified only two hepatology studies using this design: One evaluating thiamine in chronic hepatitis B and the other evaluating ursodeoxycholic acid in hepatic sarcoidosis. These findings highlight the underuse of N-of-1 trials as a potentially valuable approach for studying rare, chronic, and stable liver diseases.